Myburgh J A, Shapiro M, Maier G, Meyers A M
S Afr Med J. 1976 Jul 31;50(33):1279-84.
The role of HL-A matching in the clinical outcome of 159 consecutive first cadaver renal allografts at the Johannesburg General Hospital has been analysed over a 7-year period, April 1968-May 1975. Over-all actuarial graft survival was 69% at 1 year and 57% at 7 years. When all cases were considered together there was a trend towards improved graft survival with better grades of matching, but this was not statistically significant. Presensitisation had an adverse effect on graft survival. Donor-recipient combinations with no demonstrable FOUR locus mismatches provided a significantly superior graft survival rate of 82% 1-6 years after transplantation. The majority of these compatible for HL-A 7, 8 OR 12, and therefore may have been matched indirectly for lymphocyte activating determinants. Relatively inferior graft survival was observed with FOUR locus incompatibility in patients who had been presensitised, and when donor-recipient combinations had no serologically determined antigens in common, particularly in the donor "full house" situation. Despite these unfavourable immunogenetic circumstances, approximately 50% of grafts functioned well for long periods, and not infrequently clinical considerations took precedence over immunological considerations in the selection of recipients. This policy is justified by over-all results, the critical shortage of cadaver organs in relation to clinical requirements and the rare occurrence of combinations with superior HL-A matching. Specific allograft tolerance remains the goal of clinical organ transplantation.
1968年4月至1975年5月的7年期间,对约翰内斯堡综合医院连续159例首次尸体肾移植临床结果中HL-A配型的作用进行了分析。总体精算移植存活率1年时为69%,7年时为57%。将所有病例综合考虑,配型等级越高移植存活率有提高的趋势,但无统计学意义。预致敏对移植存活率有不利影响。无明显四个位点错配的供受者组合移植后1至6年的移植存活率显著更高,为82%。其中大多数HL-A 7、8或12配型相合,因此可能是间接配型了淋巴细胞激活决定簇。在预致敏患者中,四个位点不相容时以及供受者组合无血清学确定的共同抗原时,尤其是供者“全位点”情况时,观察到移植存活率相对较低。尽管存在这些不利的免疫遗传学情况,但约50%的移植肾长期功能良好,而且在选择受者时临床考虑常常优先于免疫考虑。总体结果、尸体器官相对于临床需求的严重短缺以及HL-A高配型组合的罕见情况证明了这一策略的合理性。特异性同种异体移植耐受仍然是临床器官移植的目标。